Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Haemonetics Q2 2026 Results: Net Income $46.3M, Up 19.7% YoY

Haemonetics Corp reported net revenues of $357.8 million for the quarter ended September 26, 2026, a 9.3% increase compared to the prior year. Net income rose to $46.3 million, driven by higher gross profits and the absence of intangible asset impairments that occurred in the previous year's quarter.

Watch the Haemonetics Corp earnings callFull call on the ALFA USA YouTube channel
Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue357.8327.3
Gross profit220.9194.7
Profit before tax62.951.3
Net income46.338.7
EPS (diluted, $ a share)$1.00$0.81

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+19.7%
Revenue, year on year+9.3%
Gross margin61.7%
Operating margin21.0%
Source

10-Q filed with the SEC, NYSE: HAE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Haemonetics Corp: key numbers

Share price
$121.34Close, Nov 16
Market cap
$5.53B
Shares outstanding
45.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Haemonetics Corp

All →
4:17 PM ET Form 4
Insider Selling

Haemonetics VP, CAO Farris Maryanne Maunsell Sells $101K of Stock

Farris Maryanne Maunsell, VP, CAO, sold 836 shares of Haemonetics Corp at $120.99 a share, worth $101K in total on Nov 11, 2026. Shares held after the trade: 5,828 (-12.5%).

Value
$101K
Shares
836
Price
$120.99
Role
VP, CAO
Holding change
-12.5%
Trade date
Nov 11, 2026
6:06 AM ET 8-K
Financial Results

Haemonetics Financial Results

Haemonetics reported second quarter fiscal 2027 revenue of $358 million, a 9% increase driven by strong performance in its Apheresis business. The company achieved GAAP diluted EPS of $1.00 and adjusted diluted EPS of $1.35, benefiting from gross margin expansion and the transformation of its product portfolio toward higher-margin offerings.

Term
Q2 2027

“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”

Chris Simon, Haemonetics’ CEO
6:15 AM ET 8-K
Business Update

Haemonetics Business Update

Haemonetics provided a status update on its non-exclusive supply agreement with CSL Plasma, noting that CSL expects to complete the rollout of NexSys PCS devices and Persona PLUS disposables across all its U.S. collection centers by the end of 2027. The company maintained its existing fiscal 2027 guidance and plans to provide a detailed financial impact update during its November 2026 earnings call.

Counterparty
CSL Plasma Inc.
Term
through end of calendar year 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.